SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) — ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation RNA therapeutics, today announced that Zhen Li, PhD, Co-Founder, President and CEO, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14 at 8:00 a.m. PT in San Francisco, California.
About ADARx Pharmaceuticals
ADARx Pharmaceuticals, Inc. is a late-stage clinical biotechnology company dedicated to transforming cutting-edge science into next-generation RNA medicines across a wide range of therapeutic areas. Our goal is to control the expression of specific disease drivers with highly selective RNA targeted therapies, delivering life-changing treatments for patients with urgent unmet medical needs. We are focused on advancing and expanding a deep pipeline of highly potent, durable and selective RNA-targeted therapeutic candidates, initially developing our product candidates for the treatment of complement-mediated, genetic, cardiovascular, central nervous system and metabolic (obesity) diseases. Follow ADARx on LinkedIn.
CONTACT: Media Contact: Teri Dahlman Red House Communications teri@redhousecomms.com
Company reports 300% revenue growth in 2024 and advances partnerships with nation's leading health systems…
SANTA CLARA, Calif., Jan. 10, 2025 /PRNewswire/ -- Anatomage Inc., a leader in medical education…
RADNOR, Pa., Jan. 10, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider…
COPENHAGEN, Denmark, Jan. 10, 2025 /PRNewswire/ -- Cmbio®, a global leader in multi-omics science and…
Partnership Will Harness NYSCF's Automated Cell Culture Systems and Artificial Intelligence Capabilities to Study Disease at…
MINNEAPOLIS, Jan. 10, 2025 /PRNewswire/ -- Bio-Techne (NASDAQ: TECH), a global leader in life science…